Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?-Reference-Cited by-同舟云学术

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Published:2022-12-20 Issue:36 Volume:40 Page:4173-4177
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Tisseverasinghe Steven¹^ORCID,Tolba Marwan¹^ORCID,Saad Fred²^ORCID,Gravis Gwenaëlle³^ORCID,Bahoric Boris¹,Niazi Tamim¹^ORCID

Affiliation:

1. Department of Radiation Oncology, McGill University, Montreal, QC, Canada

2. Center Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada

3. Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00883

Reference33 articles.

1. Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality

2. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

3. Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer

4. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial

5. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: A nationwide, multi-center, population-based cross-sectional study;Chinese Medical Journal;2024-04-12

2. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer;Current Oncology Reports;2024-02-20

3. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial;The Prostate;2024-02-04

4. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer;Advances in Therapy;2023-09-15

5. How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?;Research and Reports in Urology;2023-01